참고문헌
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. https://doi.org/10.1002/ijc.29210
- DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 2016;66:31-42. https://doi.org/10.3322/caac.21320
- Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol 2014;15:e279-89. https://doi.org/10.1016/S1470-2045(13)70567-9
- Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 2015;15:321-33. https://doi.org/10.1038/nrc3932
- Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77. https://doi.org/10.1038/nri2326
- Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 2016;44:955-72. https://doi.org/10.1016/j.immuni.2016.05.002
- Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. Immunity 2016;44:1069-78. https://doi.org/10.1016/j.immuni.2016.04.023
- Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget 2016;7:45370-84.
- Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang T, et al. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun 2016;7:11406. https://doi.org/10.1038/ncomms11406
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-40. https://doi.org/10.1093/bioinformatics/btp616
- Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012;7:e51862. https://doi.org/10.1371/journal.pone.0051862
- Gibson J. Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol 2015;16:e264.
- Wu R, Li F, Zhu J, Tang R, Qi Q, Zhou X, et al. A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population. Med Oncol 2014;31:60. https://doi.org/10.1007/s12032-014-0060-2
- Yuan SM, Li H, Yang M, Zha H, Sun H, Li XR, et al. High intensity focused ultrasound enhances anti-tumor immunity by inhibiting the negative regulatory effect of miR-134 on CD86 in a murine melanoma model. Oncotarget 2015;6:37626-37.
- Wu L, Chen Z, Zhang J, Xing Y. Effect of miR-513a-5p on etoposidestimulating B7-H1 expression in retinoblastoma cells. J Huazhong Univ Sci Technolog Med Sci 2012;32:601-6. https://doi.org/10.1007/s11596-012-1004-8
- Guo W, Tan W, Liu S, Huang X, Lin J, Liang R, et al. MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. Tumour Biol 2015;36:9049-57. https://doi.org/10.1007/s13277-015-3644-3
- Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y, et al. MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol 2014;75:348-53. https://doi.org/10.1016/j.humimm.2014.01.006
- Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014;5:5241. https://doi.org/10.1038/ncomms6241
- Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal 2015;27:443-52. https://doi.org/10.1016/j.cellsig.2014.12.003
- Yang P, Tang R, Zhu J, Zou L, Wu R, Zhou H, et al. A functional variant at miR-24 binding site in B7-H2 alters susceptibility to gastric cancer in a Chinese Han population. Mol Immunol 2013;56:98-103. https://doi.org/10.1016/j.molimm.2013.04.010
- Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 2009;69:6275-81. https://doi.org/10.1158/0008-5472.CAN-08-4517
- Wang ZS, Zhong M, Bian YH, Mu YF, Qin SL, Yu MH, et al. MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer. Oncotarget 2016;7:44266-76.
- Wang L, Kang FB, Sun N, Wang J, Chen W, Li D, et al. The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma. Tumour Biol 2016;37:14939-47. https://doi.org/10.1007/s13277-016-5386-2
- Zhou X, Mao Y, Zhu J, Meng F, Chen Q, Tao L, et al. TGF-beta1 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155/miR-143 axis. Oncotarget 2016;7:67196-211.
- Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Droeser RA, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014;146:15-24. https://doi.org/10.1007/s10549-014-2988-5
- Baptista MZ, Sarian LO, Derchain SF, Pinto GA, Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol 2016;47:78-84. https://doi.org/10.1016/j.humpath.2015.09.006
- Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Menetrier-Caux C. ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells. Oncoimmunology 2013;2:e23185. https://doi.org/10.4161/onci.23185
- Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, et al. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget 2015;6:3452-61.
- Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 2010;252:1044-51. https://doi.org/10.1097/SLA.0b013e3181f1939d
- Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, et al. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin Cancer Res 2017;23:825-32. https://doi.org/10.1158/1078-0432.CCR-15-3071
피인용 문헌
- The Regulatory Role of MicroRNAs in Breast Cancer vol.20, pp.19, 2018, https://doi.org/10.3390/ijms20194940
- Protective effect of HSA‐MIR ‐570‐3p targeting CD274 on triple negative breast cancer by blocking PI3K / AKT / M vol.36, pp.8, 2018, https://doi.org/10.1002/kjm2.12212
- MiR-4458/human antigen R (HuR) modulates PBX3 mRNA stability in melanoma tumorigenesis vol.312, pp.9, 2018, https://doi.org/10.1007/s00403-020-02051-8
- miR-301b-3p Regulates Breast Cancer Cell Proliferation, Migration, and Invasion by Targeting NR3C2 vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/8810517
- hsa_circ_0013401 Accelerates the Growth and Metastasis and Prevents Apoptosis and Autophagy of Neuroblastoma Cells by Sponging miR-195 to Release PAK2 vol.2021, pp.None, 2018, https://doi.org/10.1155/2021/9936154
- The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review vol.22, pp.5, 2018, https://doi.org/10.3390/ijms22052652
- Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis vol.12, pp.4, 2018, https://doi.org/10.3390/genes12040549
- A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery vol.12, pp.8, 2018, https://doi.org/10.3390/genes12081206
- miR‑497/MIR497HG inhibits glioma cell proliferation by targeting CCNE1 and the miR‑588/TUSC1 axis vol.46, pp.6, 2018, https://doi.org/10.3892/or.2021.8206